Lucia Ciglar,
Scientist,
AIT Austrian Institute of Technology (AIT)
Lucia Ciglar is a scientist specializing in the discovery and validation of circulating biomarkers within the Molecular Diagnostics unit at the Austrian Institute of Technology (AIT) in Vienna. With a Ph.D. in molecular biology and expertise in functional genomics, her current research focuses particularly on EV-derived miRNAs and multi-omics approaches in liquid biopsies. The Biomarker group at AIT has a profound expertise in developing and implementing high throughput multi-omics technologies. This includes utilizing DNA- and protein microarrays, next-generation sequencing (NGS), microfluidic quantitative PCR, and multiplex bead technology to comprehensively characterize complex diseases. AIT actively collaborates as a partner and WP leader in ImmUniverse, a large EU-wide effort dedicated to identifying circulating signatures for atopic dermatitis and ulcerative colitis.
Multi-Omics and EV-based Biomarkers For Complex Disease Diagnostics From Blood, Saliva or Cerebrospinal Fluid
Tuesday, 25 June 2024 at 14:00
Add to Calendar ▼2024-06-25 14:00:002024-06-25 15:00:00Europe/LondonMulti-Omics and EV-based Biomarkers For Complex Disease Diagnostics From Blood, Saliva or Cerebrospinal FluidPoint-of-Care, Biosensors and Rapid Dx Europe 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
The discovery and validation of circulating biomarkers for minimally invasive diagnostics of complex diseases have been a major focus of AIT’s Molecular Diagnostics group. Multi-omics approaches for biomarker development from both tissue and cell-free body fluids, including the utilization of EV-derived miRNAs, have been successfully established. In this presentation, the extensive multi-omics technology workflows developed by our research group will be introduced and selected results from a study conducted on patients with coronary artery disease will be highlighted, demonstrating the power of integrating various omics layers to identify and validate circulating biomarkers. Additionally, diverse EV biomarker studies will be reported, showcasing research across a range of diseases, including metabolic, immune-mediated, and cardiovascular diseases. EVs derived from different biofluids, such as serum, plasma, cell-free saliva, and cerebrospinal fluid, have been utilized, demonstrating the versatility and promise of EVs in disease diagnostics.
Add to Calendar ▼2024-06-24 00:00:002024-06-25 00:00:00Europe/LondonPoint-of-Care, Biosensors and Rapid Dx Europe 2024Point-of-Care, Biosensors and Rapid Dx Europe 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2024-06-25 14:00:002024-06-25 15:00:00Europe/LondonMulti-Omics and EV-based Biomarkers For Complex Disease Diagnostics From Blood, Saliva or Cerebrospinal FluidPoint-of-Care, Biosensors and Rapid Dx Europe 2024 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
